GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Tazbentetol

Company
Spinogenix
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT05882695

    Study of SPG302 in Healthy Volunteers and ALS Participants

    Not yet reported Spinogenix 88 participants Est. completion 2025-06-27 4 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT06427668

    Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

    Not yet reported Spinogenix 24 participants Est. completion 2026-06 2 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Active, not recruiting NCT NCT06442462

    Study of SPG302 in Adults With Schizophrenia

    Not yet reported Spinogenix 32 participants Est. completion 2026-03 3 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT06833281

    Extension Study of Participants From SPG302-ALZ-101

    Not yet reported Spinogenix 12 participants Est. completion 2025-10-09 2 sites Stand-alone
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Terminated NCT NCT06903286

    Extension Study of Participants From SPG302-ALS-001

    Not yet reported Spinogenix 16 participants Est. completion 2025-08-31 3 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis (ALS)
    View official trial listing →
  • Available NCT NCT07088159

    Intermediate-size Patient Population Expanded Access Protocol

    Spinogenix 15 sites
    Other conditions: ALS (Amyotrophic Lateral Sclerosis)
    View official trial listing →
  • Not yet recruiting NCT NCT07325591

    Efficacy and Safety of Tazbentetol in ALS Participants

    Not yet reported, Not yet reported Spinogenix 430 participants Est. completion 2028-03-01 Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Tazbentetol, SPG302

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.